Stock ETNB 89BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Sector Chart 89bio, Inc.

Equities

ETNB

US2825591033

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-15 EDT 		5-day change 1st Jan Change
9.2 USD +1.21% Intraday chart for 89bio, Inc. +1.88% -17.64%
05-14 89Bio Initiates Phase 3 Enlighten-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis Patients with Compensated Cirrhosis CI
05-10 HC Wainwright Adjusts 89bio's Price Target to $29 From $31, Maintains Buy Rating MT
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes

Sector Bio Therapeutic Drugs

Capi. Sales growth Profitability Finances EV / Sales P/E ratio
89BIO, INC. Stock 89bio, Inc.
 894M - - - - -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
 111B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
 106B
BIONTECH SE Stock BioNTech SE
 22.24B -
ARGENX SE Stock argenx SE
 21.25B -
GENMAB A/S Stock Genmab A/S
 18.97B
  1. Stock Market
  2. Equities
  3. ETNB Stock
  4. Charts 89bio, Inc.
  5. Sector Chart
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW